semaglutide perdida de peso Retatrutida permite perder hasta 30 % del peso, según estudio- UCHealth Today El uso de Ozempic, el

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity

How Ozempic and GLP-1 Drugs Work Ozempic and similar drugs have several functions that make them helpful for managing diabetes and weight loss

Addressing obesity with KD Obesity is a growing but often neglected public health issue around the world, despite dietary guidelines and recommendations

Remember, precise dosing and ongoing monitoring are vital steps that pave the way for a healthier future